These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 37267120)
21. Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism. Chen C; Wang S; Liu P Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597263 [TBL] [Abstract][Full Text] [Related]
22. Benefits of Iron Chelators in the Treatment of Parkinson's Disease. Zeng X; An H; Yu F; Wang K; Zheng L; Zhou W; Bao Y; Yang J; Shen N; Huang D Neurochem Res; 2021 May; 46(5):1239-1251. PubMed ID: 33646533 [TBL] [Abstract][Full Text] [Related]
23. Prophylactic treatment with transdermal deferoxamine mitigates radiation-induced skin fibrosis. Shen AH; Borrelli MR; Adem S; Deleon NMD; Patel RA; Mascharak S; Yen SJ; Sun BY; Taylor WL; Januszyk M; Nguyen DH; Momeni A; Gurtner GC; Longaker MT; Wan DC Sci Rep; 2020 Jul; 10(1):12346. PubMed ID: 32704071 [TBL] [Abstract][Full Text] [Related]
24. Deferoxamine reverses radiation induced hypovascularity during bone regeneration and repair in the murine mandible. Farberg AS; Jing XL; Monson LA; Donneys A; Tchanque-Fossuo CN; Deshpande SS; Buchman SR Bone; 2012 May; 50(5):1184-7. PubMed ID: 22314387 [TBL] [Abstract][Full Text] [Related]
26. Promotion of airway anastomotic microvascular regeneration and alleviation of airway ischemia by deferoxamine nanoparticles. Jiang X; Malkovskiy AV; Tian W; Sung YK; Sun W; Hsu JL; Manickam S; Wagh D; Joubert LM; Semenza GL; Rajadas J; Nicolls MR Biomaterials; 2014 Jan; 35(2):803-813. PubMed ID: 24161166 [TBL] [Abstract][Full Text] [Related]
27. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Ma S; Henson ES; Chen Y; Gibson SB Cell Death Dis; 2016 Jul; 7(7):e2307. PubMed ID: 27441659 [TBL] [Abstract][Full Text] [Related]
28. Deferoxamine attenuates lipopolysaccharide-induced inflammatory responses and protects against endotoxic shock in mice. Wang S; Liu C; Pan S; Miao Q; Xue J; Xun J; Zhang Y; Gao Y; Duan X; Fan Y Biochem Biophys Res Commun; 2015 Sep; 465(2):305-11. PubMed ID: 26277391 [TBL] [Abstract][Full Text] [Related]
29. The long-acting parenteral iron chelator, hydroxyethyl starch-deferoxamine, fails to protect against alcohol-induced liver injury in rats. Sadrzadeh SM; Hallaway PE; Nanji AA J Pharmacol Exp Ther; 1997 Feb; 280(2):1038-42. PubMed ID: 9023321 [TBL] [Abstract][Full Text] [Related]
30. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth. Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731 [TBL] [Abstract][Full Text] [Related]
31. Trypanosoma cruzi: effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice. Francisco AF; de Abreu Vieira PM; Arantes JM; Pedrosa ML; Martins HR; Silva M; Veloso VM; de Lana M; Bahia MT; Tafuri WL; Carneiro CM Exp Parasitol; 2008 Dec; 120(4):314-9. PubMed ID: 18789321 [TBL] [Abstract][Full Text] [Related]
32. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Tajima S; Ikeda Y; Sawada K; Yamano N; Horinouchi Y; Kihira Y; Ishizawa K; Izawa-Ishizawa Y; Kawazoe K; Tomita S; Minakuchi K; Tsuchiya K; Tamaki T Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E77-86. PubMed ID: 21917632 [TBL] [Abstract][Full Text] [Related]
33. [Effects of adipose-derived mesenchymal stem cells from type 2 diabetes mellitus patients on wound healing of pressure ulcers in mice]. Deng CL; Yao YZ; Liu ZY; Wang B; Wang DL; Wei ZR Zhonghua Shao Shang Za Zhi; 2019 Jan; 35(1):40-47. PubMed ID: 30678400 [TBL] [Abstract][Full Text] [Related]
34. Iron deposition-induced ferroptosis in alveolar type II cells promotes the development of pulmonary fibrosis. Cheng H; Feng D; Li X; Gao L; Tang S; Liu W; Wu X; Yue S; Li C; Luo Z Biochim Biophys Acta Mol Basis Dis; 2021 Dec; 1867(12):166204. PubMed ID: 34175430 [TBL] [Abstract][Full Text] [Related]
35. Dextran-coupled deferoxamine improves outcome in a murine model of head injury. Panter SS; Braughler JM; Hall ED J Neurotrauma; 1992; 9(1):47-53. PubMed ID: 1377753 [TBL] [Abstract][Full Text] [Related]
36. Deferoxamine Alleviates Osteoarthritis by Inhibiting Chondrocyte Ferroptosis and Activating the Nrf2 Pathway. Guo Z; Lin J; Sun K; Guo J; Yao X; Wang G; Hou L; Xu J; Guo J; Guo F Front Pharmacol; 2022; 13():791376. PubMed ID: 35359876 [No Abstract] [Full Text] [Related]
37. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Becton DL; Bryles P Cancer Res; 1988 Dec; 48(24 Pt 1):7189-92. PubMed ID: 3191493 [TBL] [Abstract][Full Text] [Related]
38. The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis. Jin H; Terai S; Sakaida I J Gastroenterol; 2007 Jun; 42(6):475-84. PubMed ID: 17671763 [TBL] [Abstract][Full Text] [Related]
39. Deferoxamine-induced neurite outgrowth and synapse formation in postnatal rat dorsal root ganglion (DRG) cell cultures. Nowicki M; Kosacka J; Spanel-Borowski K; Borlak J Eur J Cell Biol; 2009 Oct; 88(10):551-62. PubMed ID: 19581022 [TBL] [Abstract][Full Text] [Related]